Iovance Biotherapeutics (IOVA) Work In Process (2023 - 2025)

Iovance Biotherapeutics (IOVA) has reported Work In Process for 3 consecutive years, with $12.1 million the latest figure, recorded in Q1 2025.

• In Q1 2025, Work In Process rose 104.4% year-over-year to $12.1 million; the TTM figure through Mar 2025 stood at $12.1 million (up 104.4% YoY), while the FY2024 annual figure was $8.8 million, up 52.46% from the prior year.
• Work In Process climbed to $12.1 million in Q1 2025 per IOVA's latest filing, from $8.8 million in the prior quarter.
• Across five years, Work In Process topped out at $12.1 million in Q1 2025 and bottomed at $4.3 million in Q3 2023.
• Historically, Work In Process has averaged $7.6 million across 3 years, with a median of $7.3 million in 2023.
• Annual changes were most pronounced in 2024 — Work In Process surged 52.46% — and 2025, when it jumped 104.4%.
• Iovance Biotherapeutics' Work In Process stood at $5.7 million in 2023, then soared by 52.46% to $8.8 million in 2024, then surged by 37.91% to $12.1 million in 2025.
• Business Quant data shows IOVA's Work In Process at $12.1 million in Q1 2025, $8.8 million in Q4 2024, and $5.9 million in Q1 2024.